XML 41 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Data (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Reportable Segment Net Revenues and Loss

The table below provides information about the Company’s segment, including significant expenses, other segment items, certain other segment expenses, and a reconciliation to net income (loss):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

License and collaboration revenue

 

$

9,698

 

 

$

14,269

 

 

$

25,634

 

 

$

33,451

 

Research and development expenses

 

 

 

 

 

 

 

 

 

 

 

 

External research and development expenses*

 

 

33,565

 

 

 

33,420

 

 

 

107,879

 

 

 

82,988

 

Employee related expenses*

 

 

27,636

 

 

 

23,899

 

 

 

84,502

 

 

 

71,494

 

General and administrative expenses

 

 

 

 

 

 

 

 

 

 

 

 

External general and administrative expenses*

 

 

6,589

 

 

 

6,078

 

 

 

18,265

 

 

 

18,774

 

Employee related expenses*

 

 

10,145

 

 

 

8,179

 

 

 

30,578

 

 

 

24,904

 

Facility and information technology related expenses*

 

 

15,116

 

 

 

14,568

 

 

 

44,076

 

 

 

42,445

 

Depreciation and amortization

 

 

5,560

 

 

 

5,475

 

 

 

16,626

 

 

 

16,482

 

Stock-based compensation

 

 

22,747

 

 

 

29,559

 

 

 

73,796

 

 

 

90,444

 

Interest and other income

 

 

(10,903

)

 

 

(12,127

)

 

 

(33,093

)

 

 

(38,166

)

Income tax expense

 

 

 

 

 

 

 

 

 

 

 

39

 

Other segment items

 

 

11,971

 

 

 

1,886

 

 

 

7,294

 

 

 

10,435

 

Net income (loss)

 

$

(112,728

)

 

$

(96,668

)

 

$

(324,289

)

 

$

(286,388

)

* Denotes significant segment expense

Other segment items includes:

Change in fair value of derivative liabilities
Change in fair value of non-controlling equity investments
Change in fair value of contingent consideration liabilities
Loss from equity method investment
Milestone expense
License and sublicenses fees
In-process research and development charges